
    
      -  double-blind, non-inferiority, prospective, parallel group trial.

        -  Experiment duration: 07 days.

        -  02 visits (days 0 and 7).

        -  Efficacy will be evaluated for persistent allergic rhinitis based on nasal symptoms
           score

        -  Adverse events evaluation.
    
  